1. Otero A, Abelleira A, Gayoso P. Occult chronic kidney disease (OCKD), and cardiovascular risk factors. Epidemiologic study. Nefrología 2005; 25(3): 275-87.

2. Nagge, J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 2002; 162: 2605-2609.

3. Hory B, Claudet MH, Magnette J, et al. Pharmacokinetic of a very low molecular weight heparin in chronic renal failure. Throm Res 1991; 63: 311-317.

4. Cadroy Y, Pourrat J, Baladre MF, et al. Delate elimination of enoxaparine in patients with chronic renal insufficiency. Throm Res 1991; 63: 385-390.

5. Goudable C, Saivin S, Houin G, et al. Pharmcokinetics of a low molecular weight heparin (Fraxiparine®) in various stages of chronic renal failure. Nephron 1991; 59: 543-545.

6. Mismetti P, Laporte-Simitsidis S, Navarro C, et al. Aging and venous thromboembolism influence the pharmacokinetics of the anti-factor Xa and anti-thrombin activities of a low molecular weight heparin (nadroparin). Thromb Haemost 1998; 79: 1162-1165.

7. Siguret V, Pautas E, Fevrier M, et al. Elderly patients treated with tinzaparin administratered once daily (175 anti-Xa IU/Kg): anti Xa and anti IIa activities over 10 days. Thromb Haemost 2000; 84: 800-804.

8. Mahe I, Aghassarian M, Drouet L, et al. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study. Thromb Haemost 2007; 97(4): 581-586.

9. Chow SL, Zammit K, West K, et al. Correlation of antifactor Xa concentrations with renal function in patients on enoxaparin. J Clin Pharmacol 2003; 43: 586-590.

10. López-Jiménez L, Montero M, González-Fajardo JA, et al.; RIETE investigators. Venous thromboembolism in very elderly patients: findings from a prospective registry (RIETE). Haematologica 2006; 91(8): 1046-51.

11. Merli GJ. Treatment of deep venous thrombosis and pulmonary embolism with low molecular weight heparin in the geriatric patient population. Clin Geriatr Med 2001; 17: 93-106.

12. Ribera JM en: Encuentro con expertos en el Tratamiento de la Enfermedad Tromboembólica Venosa. Madrid 2006.

13. Büller HR, Agnelli G, Hull RD et al. Antithrombotic Therapy for Venous Thromboembolic Disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 401S-428S.

14. Pautas E, Gouin I, Bellot O, et al. Safety profile of tinzaparin administered at a standard curative dose in two hundred very elderly patients. Drug Staf 2002; 25(10): 725-733.

15. Cestac P, Bagheri H, Lapeyre-Mestre M, et al. Utilisation and safety of low molecular weight heparins: prospective observational study in medical inpatients. Drug Staf 2003; 26: 197-207.

16. Siguret V, Pautas E, Gouin I. Low molecular weight heparin treatment in elderly subjects with or without renal insufficiency: new insights between June 2002 and March 2004. Curr Opin Pulm Med 2004; 10(5):366-370.

17. Thorevska N, Amoateng-Adjepong Y, Sabahi, R, et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin. Chest 2004; 125: 856-863.